Skip to main content

Table 2 Predictive role of exosomal cargo in tumor drug resistance

From: Potential roles and prognostic significance of exosomes in cancer drug resistance

Cancer type Exosomal contents (srug) Ref.
Colorectal cancer miR-92a-3p (5-Fu/Oxaliplatin) [55]
miR–125b (mFOLFOX6) [139]
lncRNA UCA1 (Cetuximab) [137]
A panel of miR-21-5p, miR-1246, miR1229-5p and miR-96-5p (oxaliplatin and 5-fluorouracil) [138]
Prostate cancer ITGB4 and Vinculin (Taxane) [141]
AR-V7 (Hormonal Therapy) [144]
P-glycoprotein (Docetaxel) [39]
CD44v8-10 mRNA (Docetaxel) [140]
MDR-1, MDR-3, endophilin-A2, and PABP4 (Docetaxel) [147]
miR-1290 (Docetaxel) [148]
miR-34a (Docetaxel) [142]
Breast cancer Survivin (Paclitaxel) [76]
TRPC5 [145]
TK1 and CDK9 mRNA (CDK4/6 inhibitors) [149]
lncRNA–SNHG14 (Trastuzumab) [73]
lncRNA AFAP1-AS1 (Trastuzumab) [62]
RNA H19 (Doxorubicin) [150]
GSTP1 (Adriamycin) [136]
Multiple myeloma PSMA3 and lncPSMA3-AS1 (Bortezomib) [151]
Ovarian cancer Plasma gelsolin (pGSN) [152]
Pancreatic cancer EphA2 (Gemcitabine) [153]
miR-155 (Gemcitabine) [154]
Head and neck cancer miR-196a (Cisplatin) [155]
Lung cancer miR-222-3p (Gemcitabine) [156]
miR-146a-5p (Cisplatin) [157]
miR-21 (Cisplatin) [158]
miR-425-3p (Platinum-based chemotherapy) [8, 60]
lncRNA RP11–838N2.4 (Erlotinib) [159]
Melanoma PDGFR-B (Vemurafenib) [160]
Glioblastoma miR-1238 (Temozolomide) [161]
miR-151a (Temozolomide) [82]
MET and p-MET (Temozolomide) [75]
lncSBF2-AS1 (Temozolomide) [81]
Gestational trophoblastic neoplasia miR-219a-5p (Methotrexate) [162]
Diffuse large B-cell lymphoma miR-146a [163]
miR-99a-5p and miR-125b-5p (R-CHOP regimen) [164]
Renal cell carcinoma lncARSR (Sunitinib) [72]